



6. Process for the preparation of compounds of the formula I according to Claims 1-5 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that a compound of the formula II



in which Z has the meanings indicated in Claim 1,

10 is reacted

with a compound of formula III



20 in which R¹, R² and R³ have the meanings indicated in Claim 1, and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.


- 25 7. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.
- 30
- 35 8. Compounds of the formula I and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment and/or prevention of

cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

- 5 9. Compounds according to claim 8 for the use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.
- 10
- 15 10. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
- 20 11. Set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
- 25 and
- (b) an effective amount of a further medicament active ingredient.
- 30
- 35

6. Process for the preparation of compounds of the formula I according to Claims 1-5 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that a compound of the formula II

5




in which Z has the meanings indicated in Claim 1,

10

is reacted

with a compound of formula III

15



in which R¹, R² and R³ have the meanings indicated in Claim 1, and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

20

and/or

a base or acid of the formula I is converted into one of its salts.

25

7. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.

30

35

8. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

5

9. Set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
- and
- (b) an effective amount of a further medicament active ingredient.

10

15

20

25

30

35